Top Three J.P. Morgan Takeaways

It was great to be back at this year’s J.P. Morgan Healthcare Conference, where I had the privilege to engage with so many incredible innovators. We’re all on the same mission – to reshape the future of healthcare and help patients around the globe – and it’s inspiring to witness firsthand how our peers are helping to fuel the rapid pace of innovation, particularly in oncology. Servier Pharmaceuticals is excited to partner and to make contributions to this trend in 2020 and beyond!

While a lot of ground was covered at JPM, here are three quick takeaways I’m keeping in mind now that I’m back in Boston:

• Digital health: Unsurprisingly, this was a key focus at JPM. There is so much promise and opportunity in this area, but there’s also a clear need for more alignment on what “digital health” actually means, and how we can ensure that doctors and patients can access and use new technologies to improve care, not overcomplicate it. As an industry, we can make a huge difference here.  
• Immunotherapy and cell therapy: The future in this area is brighter than ever, as more and more companies work together to get new CAR-T cell therapies onto the market. I’m particularly excited about the buzz around allogeneic CAR-Ts and the potential for the next stage of CAR-T to be more accessible, last longer and improve overall survivorship. It’s an area I’ll be continuing to watch very closely.
• Last, but definitely not least…Patient Voice: It’s now undeniable that patients want a seat at the table, and we need them to be there. More authentic patient insights can only help us do our job better, because our job is to help patients. At Servier, we’ve been committed to giving patients more voice since Day One, and we’re never going to stop.

Overall, I’m walking away from J.P. Morgan feeling very optimistic that our industry is poised to make enormous progress – it’s a new decade, and a promising era for pharma!